Prelude Therapeutics Incorporated
NASDAQ:PRLDBiotechnology
-$0.14 today
- Market cap
- $191.00M
- Beta
- 1.01
- P/E (TTM)
- -4.5
- EPS (TTM)
- -$0.94
Volume 0.23M
Average 0.38M
PRLD Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Prelude Therapeutics IncorporatedNASDAQ: PRLD
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income declines year over year
Q1 FY2026 net income of $10.39M (cash outflow) fell 67.6% year over year, behind the -39.1% change in trailing-twelve-month net income. Sequentially, it fell 36.9% from the prior quarter. Over 3 fiscal years it compounded at -4.8% a year.
Context
- Net income amounted to 819.6% of revenue in FY2025, down 997.2 pp from a year earlier.
- Net income grew in size in 2 of the last 3 fiscal years.
- FY2025 was the smallest annual figure in the 4 fiscal years shown.
What to watch
Whether net income reaches the consensus estimate from 2 analysts of -$43.16M (-56.6%) for the fiscal year ending Dec 2026, a slowdown from the -21.8% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$10.39M-36.9% QoQ
- Last fiscal yearDec 2025
- -$99.5M-21.8% YoY
- LTMMar 2026
- -$77.8M-39.1% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -67.6% | -38.0% | +29.6 pp |
| 1 year | -21.8% | -56.6% | -34.9 pp |
| 3-year CAGR | -4.8% | -41.1% | -36.2 pp |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- (99.5M) USD
- Year-over-year change
- +21.8%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (99.5M) | +21.8% |
| FY2024 | 2024-12-31 | (127.17M) | -4.4% |
| FY2023 | 2023-12-31 | (121.83M) | -5.5% |
| FY2022 | 2022-12-31 | (115.44M) | -3.4% |
| FY2021 | 2021-12-31 | (111.69M) | — |
Net Income vs competitors
How PRLD compares with its peers on the latest reported figures
- Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -39.1% is the 10th highest of 11, against a peer median of -13.0%.
- Net income amounts to 465.3% of revenue for PRLD, versus a peer median of 889.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| FY2025 | €340.16M EUR | +84.7% | +84.4% | 7587.8% | |
| LTM Mar 2026 | $133.22M USD | -9.9% | +14.2% | 1189.1% | |
| LTM Mar 2026 | $84.74M USD | -216.1% | +23.4% | 143627.1% | |
| LTM Mar 2026 | $83.01M USD | -21.5% | -9.9% | 36891.1% | |
| LTM Mar 2026 | $81.74M USD | -14.2% | -13.0% | 589.8% | |
| LTM Mar 2026 | $77.8M USD | -39.1% | -4.8% | 465.3% | |
| LTM Mar 2026 | $75.32M USD | -6.4% | -12.0% | 266.9% | |
| LTM Mar 2026 | $61.98M USD | -35.7% | -12.4% | 89.6% | |
| LTM Mar 2026 | $54.64M USD | -17.6% | +16.2% | 167.0% | |
| LTM Mar 2026 | $54.44M USD | -11.9% | +3.5% | — | |
EPRXEupraxia Pharmaceuticals Inc. | LTM Mar 2026 | $42.72M USD | +84.6% | +27.3% | — |
| Peer median (excluding PRLD) | — | -13.0% | +8.9% | 889.5% | |
Competitors are the stored peer set for PRLD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (111.69M) | (115.44M) | (121.83M) | (127.17M) | (99.5M) |
| Depreciation & Amortization | 915K | 1.32M | 1.17M | 1.77M | 1.34M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 20.93M | 25.14M | 25.62M | 21.35M | 11.91M |
| Change in Working Capital | 3.63M | 932K | (10.48M) | 4.22M | 28.41M |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 3.9M | (347K) | (2.27M) | 3.31M | (3.92M) |
| Other Working Capital | (278K) | 1.28M | (8.21M) | 911K | 32.33M |
| Other Non-Cash Items | 2.69M | 4.31M | (1.54M) | (3.05M) | 1.53M |
| Operating Cash Flow | (83.53M) | (83.73M) | (107.06M) | (102.89M) | (56.3M) |
| Capital Expenditures | (2.32M) | (3.02M) | (3.51M) | (764K) | (67K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | (261.48M) | (119.22M) | (221.63M) | (52.69M) | (100.87M) |
| Sales of Investments | 0 | 203.93M | 190.5M | 143.65M | 154.39M |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (263.8M) | 81.69M | (34.65M) | 90.19M | 53.46M |
| Debt Repayment | 0 | 0 | 0 | (395K) | (208K) |
| Common Stock Issued | 161.42M | 815K | 135.73M | 329K | 25.04M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 3.47M | 0 | 664K | (54K) | (17K) |
| Financing Cash Flow | 164.9M | 815K | 136.4M | (120K) | 24.82M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (182.44M) | (1.22M) | (5.31M) | (12.82M) | 21.97M |
| Free Cash Flow | (85.85M) | (86.75M) | (110.58M) | (103.65M) | (56.37M) |
Prelude Therapeutics Incorporated
NASDAQ:PRLD
Intrinsic Alpha fair value
Locked
Current Price
$3.30
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.